Open an account

Enanta Pharmaceuticals

ENTA · NASDAQ

$11.67+$0.26 (+2.28%)TodayMarket closed ·
Prev close $11.41

About ENTA

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. The company is headquartered in Watertown, Massachusetts and currently employs 120 full-time employees. The company went IPO on 2013-03-21. The firm is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Company’s clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including receptor tyrosine kinase (KIT) and STAT6 inhibition. The firm has two clinical-stage product candidates for RSV, which are zelicapavir and EDP-323. Glecaprevir, a protease inhibitor discovered by the Company, is part of one of the treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in various countries under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). The firm also has development programs in virology for SARS-CoV-2 and Hepatitis B virus.

Employees
120
Headquarters
Watertown, Massachusetts
Listed
Mar 21, 2013
Sector
Health Care
Industry
Biotechnology
Website
enanta.com

ENTA key statistics

Market cap
339.89M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
259.94K
Volume
164.93K
Open price
$11.43
High today
$11.85
Low today
$11.41
52 Week high
$17.15
52 Week low
$10.20

Enanta Pharmaceuticals (ENTA) at a glance

As of Oct 20, 2026, Enanta Pharmaceuticals (ENTA) shares are priced at $11.67, giving the company a market cap of 339.89M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $11.41 and $11.85. The current price is 2.3% above the day's low and 1.5% below its high.

Volume so far is 164.93K shares, below the average of 259.94K shares a day.

Over the past year Enanta Pharmaceuticals has ranged from $10.20 to $17.15, and now sits 21% of the way up that range.

Enanta Pharmaceuticals met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q3 FY26 it reported -$0.67 per share against an estimate of -$0.5202.

The average analyst price target is $22.85, 95.8% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 8 analystsAvg $22.85
Low
$20.20
Now
$11.67
High
$33.60

ENTA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 23.7% on average.

  1. Q4 FY24: reported -$1.36 per share against an estimate of -$1.18
  2. Q1 FY25: reported -$1.05 per share against an estimate of -$1.38
  3. Q2 FY25: reported -$1.06 per share against an estimate of -$1.16
  4. Q3 FY25: reported -$0.85 per share against an estimate of -$1.30
  5. Q4 FY25: reported -$0.87 per share against an estimate of -$1.04
  6. Q1 FY26: reported -$0.42 per share against an estimate of -$0.8237
  7. Q2 FY26: reported -$0.45 per share against an estimate of -$0.4978
  8. Q3 FY26: reported -$0.67 per share against an estimate of -$0.5202

ENTA news

  • Press releaseBusiness Wire

    Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026

  • Press releaseBusiness Wire

    Enanta Pharmaceuticals to Participate in September Investor Conferences

  • Press releaseBusiness Wire

    Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026

  • Press releaseBusiness Wire

    Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus

  • Press releaseBusiness Wire

    Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)

  • Press releaseBusiness Wire

    Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

  • European Medicines Agency Announces Meeting highlights From The Committee For Medicinal Products for Human Use, May 18-21

  • Press releaseBusiness Wire

    Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026

Similar companies

Companies in the same industry as Enanta Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.